How to Inject Semaglutide Safely at Home

Is your semaglutide a pen or a vial?

Semaglutide is available as Ozempic and Wegovy injections and as Ozempic, Wegovy and Rybelsus tablets [4][5][6][7]. The two weekly injections come as pens [1][2]. The tablets are swallowed daily and follow different rules entirely [8][2].

The injection and the tablet are not interchangeable milligram for milligram. Oral bioavailability is about 1% to 2% for the Wegovy tablet compared with 89% for subcutaneous injection [2].

Everything below is about the injection.

What the labels instruct

For Ozempic, the label says the solution should look clear and colorless before use, and that the pen should not be used if particulate matter or coloration is visible [1]. The label also says to inject once weekly, on the same day each week, at any time of day, with or without meals; to inject subcutaneously into the abdomen, thigh or upper arm, using a different injection site each week when injecting in the same body region; and never to share a pen between patients, even if the needle is changed, because of the risk of transmitting blood-borne pathogens [1].

The Ozempic label also gives instructions for missed doses. If a dose is missed, the label says to give it within 5 days of the missed dose; if more than 5 days have passed, skip the missed dose and give the next dose on the regularly scheduled day [1].

If you also use insulin, the Ozempic label says to give the two as separate injections and never mix them. The same body region is acceptable, but the injections should not be adjacent [1].

The Wegovy label reports similar semaglutide exposure whether the dose goes into the abdomen, thigh or upper arm, and its warnings say the FlexTouch pen must never be shared [2].

Ozempic and Wegovy pens each come with their own instructions for use; the label text above covers timing, sites, sharing and missed doses [1][2].

Where to inject

Three regions are approved for Ozempic: abdomen, thigh and upper arm [1]. Whichever you choose, the Ozempic label says to use a different spot within that same region each week [1]. The Wegovy label reports similar semaglutide exposure after injections into the abdomen, thigh and upper arm [2].

Reading the dose on the pen

The labeled schedules differ by product and by where a person is in the schedule [1][2].

Wegovy injection (adults, weight management): 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, then maintenance from week 17 at 2.4 mg (recommended) or 1.7 mg. Adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go up to a maximum of 7.2 mg weekly. Pediatric patients 12 and older top out at 2.4 mg [2].

Ozempic injection: 0.25 mg once weekly for 4 weeks, a dose the label states is not a maintenance dose, then 0.5 mg. Maintenance is 0.5 mg, 1 mg or 2 mg, and each increase comes only after at least 4 weeks on the current dose. The maximum is 2 mg weekly [1].

The Ozempic label says to follow its dose escalation to reduce the risk of gastrointestinal adverse reactions [1]. Those reactions are common and rise with dose. In pooled Ozempic trials, nausea occurred in 6.1% of patients on placebo, 15.8% on 0.5 mg and 20.3% on 1 mg [1].

Multi-dose vials of compounded semaglutide

Compounded injectable semaglutide can be dispensed in multi-dose vials. FDA has reported dosing errors with compounded injectable semaglutide, including patients measuring the wrong dose, clinicians miscalculating, and doses above the labeled dose [3]. Compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing [3].

FDA's handling advice for multi-dose vials of sterile medicines: use a new sterile needle and syringe for every dose, and discard the vial within 28 days of first use, even if medication remains, and even if the compounder's instructions say it can be used longer [3].

Storage and shipping

FDA says injectable GLP-1 drugs require refrigeration as indicated in their package inserts, and the agency has received complaints that some compounded GLP-1 drugs arrived warm or with inadequate ice packs. FDA recommends not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, since this can affect the drug's quality [3].

What to watch after a dose

The label warnings that matter most when you inject at home [1][2]:

• Pancreatitis. Persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. The label says to discontinue if pancreatitis is suspected [1].
• Serious allergic reactions. Anaphylaxis and angioedema have been reported; the label says to discontinue and treat promptly [1].
• Severe gastrointestinal reactions. In Wegovy injection trials these occurred in 4.1% of participants versus 0.9% on placebo [2].
• Injection site reactions. Reported in 1.4% of Wegovy-treated participants versus 1% on placebo [2].
• Hypoglycemia when combined with insulin or a sulfonylurea; the label suggests considering a lower dose of the insulin or secretagogue when starting [1].

Semaglutide also carries a boxed warning about thyroid C-cell tumors seen in rodents, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [2].

Timing notes: semaglutide has a half-life of about 1 week, and the Wegovy label estimates that the drug stays in the body about 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection [2]. Ozempic's label allows the weekday to change as long as doses are more than 48 hours apart [1]. With Wegovy, a missed dose can be taken if the next scheduled dose is more than 2 days away, and after 2 or more consecutive missed doses the label directs re-escalation from a lower dose [2].